Clinical Trial Update: Effects of HQK-1001 in Patients With Sickle Cell Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating HQK-1001 in patients with sickle cell disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• HQK-1001

Snippet

Sponsor: HemaQuest Pharmaceuticals Inc. | Conditions: Sickle Cell Disease, Sickle Cell Anemia | Phase 2 | Status: TERMINATED